AUS
NZ
UK
CA
USA
IND
Healthcare
Is This ASX 200 Health Tech Stock Under Pressure During Dividend Week?
February 20, 2026 06:18 PM AEDT| By SamPro Medicus (ASX:PME) sees share movement during dividend week as investors assess contract timing within the ASX 200 healthcare technology sector.
Telix Pharmaceuticals Advances Within ASX 200 After Strong FY Update
February 20, 2026 02:47 PM AEDT| By SamTelix Pharmaceuticals (ASX:TLX) reports strong full-year revenue expansion, highlighting commercial momentum within the ASX 200 healthcare sector.
Is This All Ordinaries Health Tech Stock Expanding After New Share Quotation?
February 20, 2026 12:47 PM AEDT| By SamEchoIQ (ASX:EIQ) seeks quotation of newly issued shares, reflecting capital management activity within the All Ordinaries healthcare segment.
Neuren’s Buyback Shift: What It Means for Market Confidence on the asx 200
February 20, 2026 12:25 PM AEDT| By SamNeuren’s capital move subtly strengthens per share dynamics, reinforces confidence and maintains strategic balance within Australia’s healthcare sector.
Spotlight ASX 100 as Telix Lodges Corporate Governance Statement
February 20, 2026 12:17 PM AEDT| By SamTelix lodges its corporate governance statement and Appendix, reinforcing compliance and transparency within the ASX 100 and ASX 200 healthcare segment.
Why ASX 200 Healthcare Momentum Is Back in Focus
February 20, 2026 11:11 AM AEDT| By SamHealthcare momentum is rebuilding as established imaging platforms and disciplined pipeline expansion strengthen visibility and earnings quality across Australia’s listed market.
CSL Ltd (ASX:CSL) Share Price Guide: Key Metrics to Watch
February 19, 2026 07:32 PM AEDT| By SamAn in-depth look at CSL Ltd (ASX:CSL) covering business structure, revenue trends, profitability, and financial strength. Explore key valuation metrics shaping investor attention and understand the company’s role in global healthcare innovation.
Percheron Advances VISTA Therapy Toward Phase II Focus
February 19, 2026 05:47 PM AEDT| By SamPercheron Therapeutics advances HMBD-002 into phase II development, targeting VISTA in cancer treatment. The company highlights adaptive trials, combination strategies, and expanding immuno-oncology research opportunities.
Alcidion Group (ASX:ALC) Gains Dual SaMD Recognition for Miya Precision
February 19, 2026 03:48 PM AEDT| By SamAlcidion Group gains regulatory recognition for Miya Precision’s AI-powered clinical documentation capability in Australia and the United Kingdom, supporting healthcare workflows, structured data quality, and expansion of regulated digital health sol...
Is All Ordinaries Biotech Percheron Moving Closer to Phase Two Milestones?
February 19, 2026 11:51 AM AEDT| By SamPercheron Therapeutics secures AACR abstract acceptance as HMBD 002 advances toward Phase Two within the All Ordinaries biotech segment.
(ASX:TLX) TLX101-PX Momentum Builds Within ASX 200 Healthcare Space
February 19, 2026 03:33 AM AEDT| By Sam(ASX:TLX) advances TLX101-PX brain cancer program, reinforcing its radiopharmaceutical focus within the ASX 200 healthcare segment.
Cleo Diagnostics Advances Ovarian Cancer Test With Ella
February 18, 2026 09:06 PM AEDT| By SamCleo Diagnostics adopts an advanced diagnostic platform to strengthen ovarian cancer testing, support clinical validation, and progress regulatory pathways, highlighting innovation within the healthcare segment of the Australian market.
Hearing Technology Focus: Key Insights on COH Share Trends
February 18, 2026 06:24 PM AEDT| By SamA detailed look at Cochlear’s financial metrics, business performance, and capital strength, explaining key indicators influencing COH share trends and the company’s role in the global hearing technology industry.
Botanix Pharmaceuticals Valuation Outlook After Equity Initiative
February 18, 2026 06:14 PM AEDT| By SamAn in-depth look at Botanix Pharmaceuticals valuation outlook after its equity initiative, covering revenue expectations, capital structure changes, market sentiment, and broader trends shaping the Australian healthcare sector.
Orthocell Boosts Cash Position Within All Ordinaries Healthcare Segment
February 18, 2026 04:58 PM AEDT| By SamOrthocell strengthens liquidity after receiving a research and development tax refund, supporting regenerative medicine programs within the All Ordinaries healthcare segment.
Cyclopharm Gains NIH Nod, Expands US Technegas Reach
February 18, 2026 04:57 PM AEDT| By SamCyclopharm secures NIH approval for Technegas, strengthening its US expansion strategy, broadening clinical applications, and supporting federal healthcare adoption while advancing innovation and market presence in respiratory imaging solutions.
(ASX:PME) Half-Year Update Draws Focus Across ASX 200 Healthcare Sector
February 18, 2026 04:15 PM AEDT| By Sam(ASX:PME) reports solid half-year financial performance, reinforcing healthcare technology representation within ASX 200 and All Ordinaries indices.
Australian Clinical Labs (ASX:ACL) Faces Margin Pressure Within All Ordinaries Healthcare Segment
February 17, 2026 09:39 PM AEDT| By SamAustralian Clinical Labs reports margin compression amid shifting testing volumes, reflecting evolving dynamics within the All Ordinaries healthcare sector.
Botanix Pharma Strengthens Supply and Sofdra Expansion
February 17, 2026 08:40 PM AEDT| By SamBotanix Pharmaceuticals strengthens its supply chain and Sofdra growth strategy through a major capital raise, focusing on API sourcing, commercial expansion, and operational resilience in the evolving healthcare market.
Sonic Healthcare Shares: Value Outlook for the Year Ahead
February 17, 2026 05:37 PM AEDT| By SamA detailed look at Sonic Healthcare’s valuation outlook, covering financial performance, revenue trends, debt structure, and key metrics shaping its position within the ASX stock market and global healthcare diagnostics industry.
Advertise your brand on Kalkine Media